NCT01402843已完成3 期
A Randomized, Double Blind, Double Dummy, Placebo Controlled Phase III Trial to Evaluate the Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia(COCTAIL Study)
JW Pharmaceutical10 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2011年6月最近更新:
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 150
- 试验地点
- 10
- 主要终点
- The experimental group should be compared with control group in the change of DBP and LDL-C on the basis of the baseline.
研究概览
简要总结
Pitavastatin, a representative statin-series anti-dyslipidemic drug, and Valsartan, a representative ARB-series anti-hypertensive drug, have been authorized for use also in South Korea. They have been tested in many countries and proved to be effective and safe. The concurrence of dyslipidemia and hypertension has a higher rate, hence statin-series drugs and antihypertensive drugs are simultaneously administered to such patients. The combined administration of statin-series drugs and CCB-series drugs have.
详细描述
This clinical trial was conducted to evaluate the safety and effectiveness of the combined administration of Pitavastatin and Valsartan to ethnic Koreans with dyslipidemia concurrent with hypertension, as well as to research the influence on the pharmacodynamic interaction between the two drugs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 20 and older
- •Patients with Dyslipidemia
- •Patients with hypertension
- •Patients who voluntarily signed the consent form.
排除标准
- •Blood Pressure
- •In case there is a sitting systolic blood pressure difference of 20mmHg and over or sitting diastolic blood pressure is 10mmHg and over in selected arm.
- •Patients with symptomatic orthostatic hypotension.
- •Patients having the history of Secondary hypertension or suspected to be Secondary hypertension, e.g., aortic coarctation, hyperaldosteronism, renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic renal disease, etc.
- •Patients with severe heart diseases (NYHA class-III and IV), with ischemic heart diseases (angina pectoris and myocardial infarction) and with peripheral vascular diseases, and patients who underwent percutaneous transluminal coronary angioplasty (PTCA) or treatments for coronary artery bypass graft within 6 months.
- •Patients with clinically significant ventricular tachycardia or atrial fibrillation or atrial flutter, and patients with arrhythmia judged to be clinically significant by investigators.
- •Patients with hypertrophic obstructive cardiomyopathy, severe obstructive CAD, aortic stenosis and hemodynamically significant aortostenosis or mitral stenosis.
- •Patients with severe cerebrovascular diseases.
- •Patients with severe or malignant retinosis.
- •Patients with consumption diseases or autoimmune diseases or connective tissue diseases
- •Patients with endocrine or metabolic diseases that are known to affect serum lipid or lipoprotein.
- •Patients with uncontrollable diabetes
- •Patients with uncontrollable thyroid dysfunction
- •Patients who underwent treatments that may affect lipid before the clinical trial.
- •Patients having the history of myopathy or rhabdomyolysis.
- •Patients with severe renal disorders or hepatic disorders.
- •Patients with gastrointestinal diseases that may affect drug absorption, distribution, metabolism and excretion or who underwent such operations, or patients with present active gastritis or gastrointestinal hemorrhage or proctorrhagia or active and inflammatory bowel syndrome that has occurred within 12 months.
- •All of patients with chronic inflammatory diseases whereto anti-inflammatory treatments need to be applied.
- •Patients having the history of drug or alcohol abuse.
- •Pregnant women and/or women in the lactation period or the child-bearing period.
- •Patients who are hypersensitive to Pitavastatin and Valsartan.
- •Patients who have taken other investigational drugs within 3 months before undergoing the screening test for this clinical trial.
- •Patients judged to be unsuitable for this clinical trial by investigators.
研究组 & 干预措施
pitavastatin + valsartan
Experimental
干预措施: pitavastatin, valsartan, placebo (Drug)
pitavastatin + placebo
Placebo Comparator
干预措施: pitavastatin, valsartan, placebo (Drug)
valsartan + placebo
Placebo Comparator
干预措施: pitavastatin, valsartan, placebo (Drug)
placebo
Placebo Comparator
干预措施: pitavastatin, valsartan, placebo (Drug)
结局指标
主要结局
The experimental group should be compared with control group in the change of DBP and LDL-C on the basis of the baseline.
时间窗: 8 week
次要结局
- Change from Baseline in Systolic Blood Pressure at 6 months.(8 week)
- The changes and rate of lipid variables (TG, TC, HDL cholesterol and apolipoprotein B)(8 week)
研究者
研究点 (10)
Loading locations...
相似试验
撤回
3 期
Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple SclerosisRelapsing Remitting Multiple SclerosisNCT00429442Anna Tsakiri
已完成
3 期
A Clinical Trial to Evaluate the Efficacy and Safety of Pitavastatin/Fenofibrate in Complex-dyslipidemiaComplex-dyslipidemiaNCT03618797Hanlim Pharm. Co., Ltd.347
已完成
1 期
Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy SubjectsHypertensionHyperlipidemiaNCT01406431JW Pharmaceutical48
已完成
1 期
To Evaluate the Safety and PK Characteristics in Healthy Volunteers-LivalozetHypertensionHyperlipidemiaNCT01764178JW Pharmaceutical52
已完成
4 期
Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With PravastatinSchizoaffective DisorderSchizophreniaNCT00177580University of Pittsburgh72